Map-ISODATA demarcates regional response to combination rt-PA and 7E3 F(ab')2 treatment of embolic stroke in the rat.
OBJECTIVE
To investigate the ability of map-ISODATA (Iterative Self-Organizing Data Analysis Technique) to classify the different categories of ischemic damage in the lesion and to evaluate a combined (thrombolysis plus antiplatelet) treatment efficacy in an embolic stroke of rat.


METHODS
Rats subjected to embolic stroke with (N=12) and without (N=10) rt-PA and 7E3 F(ab')2 treatment (4 hours after embolization) were followed (at 2, 24, and 48 hours post-MCAO) with magnetic resonance imaging (MRI) using T1, T2, and apparent diffusion coefficient of water (ADCw). ISODATA was computed from T1, T2, and ADCw maps. The signatures characterized by the map-ISODATA were compared with histological quantitative evaluation and were employed to demarcate the specific regions in the lesion.


RESULTS
The signature described by map-ISODATA is highly correlated with the degree of tissue damage in the lesion and can distinguish the severity of ischemic tissue injury. Based upon map-ISODATA, ischemic lesion area can be divided into three specific regions, each characterized by a distinct evolution of injury and treatment response. The combined treatment significantly reduces the lesion size between 24 and 48 hours and improves the outcome 48 hours post-MCAO compared with the control group.


CONCLUSIONS
Map-ISODATA provides an accurate means to identify lesion area, to distinguish ischemic damage, and to detect treatment response. 7E3 F(ab')2 extends the rt-PA treatment window to at least four hours after the onset of embolic stroke of rat.
Li
Lian
L
Department of Neurology, Henry Ford Health Sciences Center, Detroit, Michigan 48202, USA.
Jiang
Quan
Q
Ding
Guangliang
G
Zhang
Li
L
Zhang
Zheng Gang
ZG
Ewing
James R
JR
Knight
Robert A
RA
Kapke
Alissa
A
Soltanian-Zadeh
Hamid
H
Chopp
Michael
M
D000704:Analysis of Variance; D000818:Animals; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D007091:Image Processing, Computer-Assisted; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology*; D002542:Intracranial Embolism and Thrombosis / Q000188:drug therapy* / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D051381:Rats; D017208:Rats, Wistar; D010959:Tissue Plasminogen Activator / Q000494:pharmacology*
D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D010959:Tissue Plasminogen Activator